![Richard M. Lipkin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard M. Lipkin
Director/Board Member at American Committee for the Weizmann Institute of Science
Profile
Richard M.
Lipkin is currently a Director at the American Committee for the Weizmann Institute of Science and a Director at Epivax Oncology, Inc. He was formerly a Principal at NSV II Management Co. LLC.
Richard M. Lipkin active positions
Companies | Position | Start |
---|---|---|
American Committee for the Weizmann Institute of Science
![]() American Committee for the Weizmann Institute of Science Miscellaneous Commercial ServicesCommercial Services American Committee for the Weizmann Institute of Science operates as a community of visionary people who advance the partnership between science and philanthropy. It partners with individuals, families, foundations, and the business community to develop philanthropic funding for the institute; educates the American public about the institute’s research; and represents the institute’s interests in the U.S. through the events such as galas, parlor meetings, and luncheons; meetings with institute scientists and campaigns to spread the news of research discovery. The company was founded by Chaim Weizmann in November 1944 and is headquartered in New York, NY. | Director/Board Member | - |
Epivax Oncology, Inc.
![]() Epivax Oncology, Inc. BiotechnologyHealth Technology Epivax Oncology, Inc. engages in computational-immunology, genomics and vaccine design. It develops mutanome-directed, neo-epitope personalized therapeutic vaccines. The company was founded by Gad Berdugo, Anne De Groot, and Martin William in 2017 and is headquartered in New York, NY. | Director/Board Member | - |
Former positions of Richard M. Lipkin
Companies | Position | End |
---|---|---|
NSV II Management Co. LLC
![]() NSV II Management Co. LLC Investment ManagersFinance NSV II Management Co. LLC provides investment management services. It is a private equity and venture capital firm specializing in investing in growth capital, growth and expansion stage, recapitalization, mid stage, late stage, mezzanine, control buyouts, mergers and acquisitions and management buyouts in middle market companies. The company was founded by Michael A. DiPiano and Marc R. Lederman in 1999 and is headquartered in Radnor, PA. | Corporate Officer/Principal | 31/12/2005 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
NSV II Management Co. LLC
![]() NSV II Management Co. LLC Investment ManagersFinance NSV II Management Co. LLC provides investment management services. It is a private equity and venture capital firm specializing in investing in growth capital, growth and expansion stage, recapitalization, mid stage, late stage, mezzanine, control buyouts, mergers and acquisitions and management buyouts in middle market companies. The company was founded by Michael A. DiPiano and Marc R. Lederman in 1999 and is headquartered in Radnor, PA. | Finance |
American Committee for the Weizmann Institute of Science
![]() American Committee for the Weizmann Institute of Science Miscellaneous Commercial ServicesCommercial Services American Committee for the Weizmann Institute of Science operates as a community of visionary people who advance the partnership between science and philanthropy. It partners with individuals, families, foundations, and the business community to develop philanthropic funding for the institute; educates the American public about the institute’s research; and represents the institute’s interests in the U.S. through the events such as galas, parlor meetings, and luncheons; meetings with institute scientists and campaigns to spread the news of research discovery. The company was founded by Chaim Weizmann in November 1944 and is headquartered in New York, NY. | Commercial Services |
Epivax Oncology, Inc.
![]() Epivax Oncology, Inc. BiotechnologyHealth Technology Epivax Oncology, Inc. engages in computational-immunology, genomics and vaccine design. It develops mutanome-directed, neo-epitope personalized therapeutic vaccines. The company was founded by Gad Berdugo, Anne De Groot, and Martin William in 2017 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Richard M. Lipkin